Compare TKNO & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | SOPH |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.3M | 374.1M |
| IPO Year | 2021 | 2021 |
| Metric | TKNO | SOPH |
|---|---|---|
| Price | $5.82 | $5.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 216.8K | ★ 333.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $8.27 | $23.09 |
| Revenue Next Year | $13.13 | $19.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $2.83 |
| 52 Week High | $6.68 | $6.30 |
| Indicator | TKNO | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | 50.94 |
| Support Level | $3.33 | $4.59 |
| Resistance Level | $5.84 | $5.65 |
| Average True Range (ATR) | 0.42 | 0.40 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 83.81 | 36.24 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.